Cell News and Research

RSS

Avon Foundation for Women awards grant to improve reconstructive breast surgery

The Avon Foundation for Women has awarded the Clemson University Institute for Biological Interfaces of Engineering a $195,000 grant to support research to develop new ways to improve reconstructive breast surgery using engineered tissue that contains anti-cancer properties.

29 Oct 2009

$5.5 million grant to Cedars-Sinai Heart Institute for development of cardiac stem cell therapies

A team of Cedars-Sinai Heart Institute stem cell researchers led by Eduardo Marbán, M.D., Ph.D. has been awarded a four-year, $5.5 million grant from the California Institute of Regenerative Medicine (CIRM) to fund research leading to clinical trials of new treatments for heart attack patients.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

NIGMS accelerates induced pluripotent stem cells study with Recovery Act funds

The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health, is using $5.4 million of Recovery Act funds to accelerate basic studies of induced pluripotent stem cells. These cells, abbreviated iPS, are reprogrammed from skin or other easily obtained adult cells and appear to be similar to stem cells derived from embryos.

28 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

StemCells to raise $12.5 million

StemCells, Inc. announced today that it has entered into an agreement to raise approximately $12.5 million in gross proceeds through the sale of approximately 10 million shares of its common stock to selected institutional investors at a price of $1.25 per share. The investors will also receive warrants to purchase approximately four million shares of common stock at an exercise price of $1.50 per share.

28 Oct 2009

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.

28 Oct 2009

First spinal surgery in the U.S. using Osteotech's MagniFuse PC bone graft technology performed

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that MagniFuse PC (Posterior Cervical) Bone Graft, a new tissue-based product built upon the Company's proprietary MagniFuse bone graft technology platform, has been used for the first time in a spinal surgery in the United States.

28 Oct 2009

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism.

28 Oct 2009

Total number of vertebrae: Hox genes have a say

Vertebrates have in common a skeleton made of segments, the vertebrae. During development of the embryo, each segment is added in a time dependent manner, from the head-end to the tail-end: the first segments to be added become the vertebrae of the neck, later segments become the vertebrae with ribs and the last ones the vertebra located in the tail (in the case of a mouse, for example). In this process, it is crucial that, on the one hand, each segment, as it matures, becomes the correct type of vertebra and, on the other, that the number of vertebrae in the skeleton, and therefore the size of the spine, are minutely controlled.

28 Oct 2009

Fastest supercomputer used to create an evolutionary genetic HIV family tree

Supporting Los Alamos National Laboratory's role in the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, researchers are using the Roadrunner supercomputer to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

New biotechnology research center launched by SHRO

The Sbarro Health Research Organization (SHRO), a nonprofit research facility located at Temple University, will dedicate a new state-of-the-art biotechnology research center on Tuesday, October 27th, at 2 p.m. SHRO is one of the top three international laboratories, based on number of publications as ranked by the Cell Cycle Registry,

28 Oct 2009

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com) and Reproductive Medicine Associates of New York (RMA of New York) have shown that immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived. Immature eggs are normally discarded during standard in vitro fertilization (IVF) procedures due to their inability to create an embryo.

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

28 Oct 2009

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Officials at Endocyte Inc., a cancer drug discovery and development company, announced Tuesday (Oct. 27, 2009) that the company has been awarded a patent from the U.S. Patent and Trademark Office covering vitamin receptor binding anti-cancer agents.

28 Oct 2009

Cell News and Research

Avon Foundation for Women awards grant to improve reconstructive breast surgery

$5.5 million grant to Cedars-Sinai Heart Institute for development of cardiac stem cell therapies

Moores UCSD Cancer Center awarded $20 million for cancer research

NIGMS accelerates induced pluripotent stem cells study with Recovery Act funds

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

StemCells to raise $12.5 million

NCI awards UAMS Myeloma Institute $19.5M grant

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Pure Protein develops soluble Class II human leukocyte antigens

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

First spinal surgery in the U.S. using Osteotech's MagniFuse PC bone graft technology performed

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Total number of vertebrae: Hox genes have a say

Fastest supercomputer used to create an evolutionary genetic HIV family tree

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

New biotechnology research center launched by SHRO

Scientific breakthrough to derive human parthenogenetic stem cell lines from unfertilized human eggs

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

U.S. PTO awards Endocyte patent for vitamin receptor binding anti-cancer agents

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News